These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37385026)

  • 1. Neuropathological analysis of cognitive impairment in progressive supranuclear palsy.
    Sakuwa M; Adachi T; Suzuki Y; Takigawa H; Hanajima R
    J Neurol Sci; 2023 Aug; 451():120718. PubMed ID: 37385026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death.
    Zhang L; Toyoshima Y; Takeshima A; Shimizu H; Tomita I; Onodera O; Takahashi H; Kakita A
    Neuropathology; 2021 Jun; 41(3):174-182. PubMed ID: 33205528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment in progressive supranuclear palsy is associated with tau burden.
    Koga S; Parks A; Kasanuki K; Sanchez-Contreras M; Baker MC; Josephs KA; Ahlskog JE; Uitti RJ; Graff-Radford N; van Gerpen JA; Wszolek ZK; Rademakers R; Dickson DW
    Mov Disord; 2017 Dec; 32(12):1772-1779. PubMed ID: 29082658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process.
    Togo T; Dickson DW
    Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.
    Roemer SF; Grinberg LT; Crary JF; Seeley WW; McKee AC; Kovacs GG; Beach TG; Duyckaerts C; Ferrer IA; Gelpi E; Lee EB; Revesz T; White CL; Yoshida M; Pereira FL; Whitney K; Ghayal NB; Dickson DW
    Acta Neuropathol; 2022 Oct; 144(4):603-614. PubMed ID: 35947184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series.
    Yoshida K; Hata Y; Kinoshita K; Takashima S; Tanaka K; Nishida N
    Acta Neuropathol; 2017 May; 133(5):809-823. PubMed ID: 28064358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between clinical and neuropathological subtypes of progressive supranuclear palsy.
    Koizumi R; Akagi A; Riku Y; Miyahara H; Sone J; Tanaka F; Yoshida M; Iwasaki Y
    Parkinsonism Relat Disord; 2024 Oct; 127():106076. PubMed ID: 38494398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autopsy case of progressive supranuclear palsy. Pallido-nigro-luysian type with argyrophilic grains clinically presenting with personality and behavioral changes.
    Suzuki Y; Adachi T; Sakuwa M; Sakata R; Takigawa H; Hasegawa M; Hanajima R
    Neuropathology; 2022 Oct; 42(5):447-452. PubMed ID: 35811445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW
    Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau.
    Beck G; Yamashita R; Kido K; Ikenaka K; Chiba T; Yonenobu Y; Saito Y; Morii E; Hasegawa M; Murayama S; Mochizuki H
    Neuropathology; 2023 Aug; 43(4):326-332. PubMed ID: 36593715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case.
    Mochizuki A; Ueda Y; Komatsuzaki Y; Tsuchiya K; Arai T; Shoji S
    Acta Neuropathol; 2003 Jun; 105(6):610-4. PubMed ID: 12669238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.
    Josephs KA; Boeve BF; Duffy JR; Smith GE; Knopman DS; Parisi JE; Petersen RC; Dickson DW
    Neurocase; 2005 Aug; 11(4):283-96. PubMed ID: 16093229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Zhou X; Dickson DW
    Neuropathol Appl Neurobiol; 2021 Dec; 47(7):931-941. PubMed ID: 33763863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between regional burden of tau pathology and age at death and disease duration in PSP.
    Badihian N; Tosakulwong N; Weigand SD; Ali F; Clark HM; Stierwalt J; Botha H; Savica R; Dickson DW; Whitwell JL; Josephs KA
    Parkinsonism Relat Disord; 2024 Oct; 127():107109. PubMed ID: 39222570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy.
    Valentino RR; Koga S; Heckman MG; Brushaber DE; Diehl NN; Walton RL; Dickson DW; Ross OA
    Mov Disord; 2020 May; 35(5):890-894. PubMed ID: 32142177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia.
    Nagao S; Yokota O; Nanba R; Takata H; Haraguchi T; Ishizu H; Ikeda C; Takeda N; Oshima E; Sakane K; Terada S; Ihara Y; Uchitomi Y
    J Neurol Sci; 2012 Dec; 323(1-2):147-53. PubMed ID: 23026537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome.
    Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H
    Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.